奥马珠单抗在慢性诱导性荨麻疹治疗中的应用进展  

Progress in the application of omalizumab in the treatment of chronic inducible urticaria

作　　者：陈紫嫣 邹荟 林天一 吴伟鸿 陈教全 梁碧华 李润祥 李华平 朱慧兰 CHEN Ziyan;ZOU Hui;LIN Tianyi;WU Weihong;CHEN Jiaoquan;LIANG Bihua;LI Runxiang;LI Huaping;ZHU Huilan(Guangzhou Dermatology Hospital,Guangzhou 510095,China;Guangzhou Medical University,Guangzhou 511495,China)

机构地区：[1]广州市皮肤病医院,广东广州510095 [2]广州医科大学,广东广州511495

出　　处：《皮肤性病诊疗学杂志》2024年第12期858-864,共7页Journal of Diagnosis and Therapy on Dermato-venereology

基　　金：广州市科技计划项目(2024A03J0559);2024年度市校(院)企联合资助项目(2024A03J0479)。

摘　　要：慢性诱导性荨麻疹(CIndU)是由独特诱因诱发的以风团、血管性水肿为常见症状的慢性荨麻疹。奥马珠单抗是一种重组人源化的抗IgE抗体,目前国际指南将其列为CIndU的三线治疗,现已有部分奥马珠单抗治疗CIndU的先例,但相关的剂量、疗效、不良反应等数据相对不足。本文旨在对奥马珠单抗在各型CIndU治疗中的疗效及治疗进展进行综述,为CIndU患者提供治疗的理论基础。Chronic inducible urticaria(CIndU)is a chronic urticaria caused by unique triggers,manifested by wheals and angioedema as common symptoms.Omalizumab is a recombinant humanized anti-IgE antibody,which is currently listed as the third-line treatment for CIndU in international guidelines,and there are some precedents for the treatment of CIndU with omalizumab,but the relevant dose,efficacy,adverse reactions and other data are relatively insufficient.The purpose of this article is to review the efficacy and treatment progress of omalizumab in the treatment of various types of CIndU,and to provide a rationale for the treatment of patients with CIndU.

关 键 词：奥马珠单抗 慢性诱导性荨麻疹 皮肤划痕征 冷接触性荨麻疹 胆碱能性荨麻疹 延迟压力性荨麻疹 

分 类 号：R75[医药卫生—皮肤病学与性病学]